Related Experiment Video

Updated: Jul 14, 2026

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

Topotecan for the treatment of small-cell lung cancer

Shibani J Nicum1, Mary E R O'Brien

  • 1Royal Marsden Hospital, London, UK. Shibani.Nicum@rmh.nhs.uk

Expert Review of Anticancer Therapy
|June 9, 2007
PubMed

Insights

Topotecan offers an effective treatment for recurrent small-cell lung cancer, including an oral option beneficial for elderly patients. This review examines its role in improving therapies for this prevalent malignancy.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Small-cell lung cancer (SCLC) is a prevalent malignancy with a high propensity for early relapse and resistance to standard treatments.
  • Current therapeutic options for recurrent SCLC require improvement to enhance patient outcomes.

Purpose of the Study:

  • To review the established role and efficacy of topotecan in the treatment of small-cell lung cancer.
  • To highlight the benefits of both intravenous and oral formulations of topotecan, particularly in challenging patient populations.

Main Methods:

  • Literature review of clinical studies and therapeutic guidelines concerning topotecan in SCLC treatment.
  • Analysis of efficacy, tolerability, and patient-specific benefits, including elderly individuals with poor performance status.

Main Results:

  • Topotecan demonstrates efficacy and tolerability as a therapeutic option for patients with recurrent SCLC.
  • The oral formulation of topotecan has shown particular benefit, even in elderly patients with poor performance status.

Conclusions:

  • Topotecan is a valuable agent in the management of recurrent small-cell lung cancer.
  • The availability of an oral formulation expands treatment accessibility and applicability for SCLC patients.

More Related Videos

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...